| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 1,918 | 1,007 |
| Depreciation and amortization | 307 | 196 |
| Amortization of deferred financing fees | 42 | 26 |
| Stock-based compensation | 31 | 24 |
| Asset impairment - lab supplies | 198 | 198 |
| Credit loss expense | - | 0 |
| Change in fair value of note payable | -87 | 18 |
| Amortization on operating lease right of use asset | 293 | 193 |
| Accounts receivable | -2,578 | -1,313 |
| Other current assets | 213 | 227 |
| Interest accretion expense | - | 0 |
| Accounts payable | -417 | -409 |
| Accrued salaries and bonus | -777 | -176 |
| Other accrued expenses | -385 | -401 |
| Operating lease liabilities | -283 | -185 |
| Bad debt expense reversal | - | 0 |
| Other long-term liabilities | 314 | 214 |
| Net cash provided by operating activities | 3,693 | 1,755 |
| Purchase of property and equipment | 318 | 201 |
| Net cash used in investing activities | -318 | -201 |
| Payments made on note payable | 3,400 | 2,500 |
| Series c conversion costs | 13 | 13 |
| Net cash used in financing activities | -3,413 | -2,513 |
| Net decrease in cash and cash equivalents | -38 | -959 |
| Cash and cash equivalents at beginning of period | 1,461 | - |
| Cash and cash equivalents at end of period | 1,423 | - |
INTERPACE BIOSCIENCES, INC. (IDXG)
INTERPACE BIOSCIENCES, INC. (IDXG)